This study analyzed potential drug interactions (PDIs) of antimicrobials used in patients of hematopoietic stem cell transplantation and identified associated factors. The sample consisted of 70 patients admitted to a hospital in São Paulo. The PDIs were analyzed through the consultation of the Drug Interactions Facts and Drug Interactions Handbook. Descriptive statistics and logistic regression were used. Half of the sample was exposed to 13 PDIs, which occurred with fluconazole (53.8%), ciprofloxacin (30.8%) and sulfamethoxazole- La mayoría (92,3%) presentó gravedad moderada, inicio de efecto demorado (61,5%) y necesidad de monitorizar la terapia (76,9%). Cuatro o más medicamentos (p<0,001), edad entre 40 y 49 años (p<0,001) y sexo masculino (p<0,001), fueron asociados al riesgo de IMP. Las implicaciones de las IMP pueden resultar en resultados adversos, causando impacto en la morbimortalidad del paciente. Los regímenes combinados pueden ser seguros, desde que exista monitorización cuidadosa por parte de los profesionales envueltos en el cuidado.
Introduction
Drug interactions (DIs) are among the main evitable causes of adverse drug events (ADEs); DIs represent 20% to 30% of these and are clinically relevant in 80% of the cases, especially among elderly individuals (1) (2) . Even though ADEs accruing from DIs are underreported, they are considered to be a health problem because there are interactions that cause treatment failure in patients without a clinical modification immediately obvious. The DI phenomenon in the hematology-oncology field is still seldom addressed despite the vulnerability of patients cared for in this specialty, particularly those undergoing hematopoietic stem cell transplantation (HSCT). In this type of therapy, the receptor's marrow aplasia is first performed and then, previously treated hematopoietic tissue cells or those from a compatible donor, are intravenously infused to reestablish hematopoiesis (5) . Exposure of patients to complex therapeutic regimes consisting of a narrow therapeutic index, toxicity in various potentially interactive organ and antimicrobial systems, association with pharmacokinetics and pharmacodynamic variability, are some of the factors that increase the risk of DI in individuals undergoing HSCT (6) (7) .
A study conducted with outpatients with solid tumors found that 27% of them presented at least one DI, which reached 31% of patients treated in a hospice care service (8) (9) . In HSCT patients treated with antifungal medication, 86% were exposed to at least one DI and 26% presented one or more ADE related to the identified DI (7) . A Brazilian study conducted in a hematology unit showed that 95.5% of the sample was exposed to an association of potentially interactive medications in the post-chemotherapy phase (10) . In a general hospital, 63% of the hematological patients with solid tumors presented at least one DI during hospitalization (11) . Even though a causal relationship is difficult to establish, the impact of DI can be very relevant. One study indicated that 4% of deaths identified in hospitalized individuals diagnosed with cancer were related to severe DIs (12) .
A review paper addressing DIs in organ transplantation patients, including bone marrow transplantation, reported that antimicrobial medication such as fluconazole, trimethoprim/sulphamethoxazole, acyclovir, and imipenem interact with cyclosporine, one of the most frequently used immunosuppressant medications in HSCT (13) . This study was conceived considering that In this study the term 'Potential Drug Interaction' (PDI) was used, which refers to the chance of a given medication altering the intensity of the pharmacological effect of another medication included in the therapy.
PDIs were classified based on studies of renowned authors (3) (4) . The effects accruing from DIs in the severity degree classified as 'Major' threaten one's life and may cause permanent damage. In 'Moderate' severity, responses may harm patients or increase their time of hospitalization, while effects in 'Minor' severity are mild and consequences may either bother the individual or even pass unnoticed, though additional therapy is required (3) .
Five categories were considered to constitution scientific evidence: Established, Likely, Suspected, Possible and Unlikely. Documentation in the category 'established' is included when there is evidence through the occurrence of DI in well-controlled studies. DI is considered 'likely' when it is typical though not clinically Guastaldi RBF, Secoli SR.
proved; 'suspected' if DI can occur, if there is some information related to the event though further studies are required. 'Possible' when DI may occur but data are very limited, and 'unlikely' when there is no evidence of alteration of clinical effects in patients (3) . Effect onset time refers to the point when an adverse effect appears and DIs are classified as 'fast' (within 24 hours) and 'delayed' (days or weeks) (3) .
The risk of mixed therapy was classified into five levels: A -there is no known occurrence of DI; Bno therapeutic action is required; C -Monitor therapy; D -Consider changing therapy; and X -Avoid mixed therapy with analyzed agents (4) . The Statistical Package for the Social Sciences (SPSS) program version 13.0 was used in data analysis. Rev. Latino-Am. Enfermagem 2011 July-Aug.;19(4):960-7.
Considering the total number of used medications (n=33), 32 distinct PDIs were identified, while 71.4%
(n=50) of the sample presented at least one PDI. In the PDI analysis of anti-microbial medication, half of the patients (n=35) were exposed to 13 PDIs.
Of these, 53.8% occurred with fluconazole, 30.8%
with ciprofloxacin and 15.4% due to the use of sulfamethoxazole+trimethoprim.
Among the patients using fluconazole (n=32) 93.7%
presented at least one PDI. Two PDIs were identified with the use of sulfamethoxazole+trimethoprim, which occurred in four different patients while four PDIs were observed in a single patient with the use of ciprofloxacin.
PDIs of anti-microbial medication were of a pharmacokinetic nature, 84.6% capable of modifying the pattern of metabolism, interfering in serum levels of the object-medication.
Most PDIs (92.3%) presented moderate severity with scientific evidence originating from non-controlled studies (53.8%), which could result in increased serum levels of the object-medication (77.0%), with delayed effect time onset (61.5%); the risk of mixed therapy involved implies the need to monitor serum levels and the toxicity of the agents involved (76.9%) ( Table 2 ).
Logistic regression indicated that being a man (OR=2.4), between 40 and 49 years of age (OR=6.1), and using four or more medications (OR=6.9) significantly increased the risk of PDI (Table 3) . 
Discussion
Patients undergoing HSCT were particularly susceptible to PDIs, not only due to their clinical particularities but also due to their pharmacological therapy profiles composed of various medications, many with potentially interactive characteristics, which were implicated in many important DIs. As indicated in previous studies, they could harm patients (7, 14) .
However, it is possible that the effects accruing from PDIs pass unnoticed in these patients or are interpreted as manifestations of a disease's clinical development because of their condition's complexity.
The relationship between the number of medications and DIs was well documented in the literature by various authors (8) (9) 11, (14) (15) . This study revealed that the chances of a PDI occurring was almost seven times greater (OR-=6.9)
when the patient used four or more medications. A recent Guastaldi RBF, Secoli SR.
study conducted in an intensive therapy unit reported a positive association between the number of medications and potential interactions on the patient's sixth day of hospitalization (15) . Oncologic studies addressing different contexts concluded that the number of medications was also a predictive factor for DIs (8) (9) 11) . Regardless of the investigation's context, these authors analyzed clinically chronic (8) (9) 11) and severely acute (15) patients. Hence, the complexity of the therapy is closely related to the risk of PDIs, whether these are mild or severe.
Being between 40 to 49 years old was also a factor associated with PDIs. However, being within the older ages in the different age ranges (30-39 years old, OR=1.54 and 50 years old or older, OR=1.61) was an indicator of risk for PDIs, even though for those between 30 and 39 years old no statistically significant difference (p=0.054) was found for the level of significance at 5%. It is possible that this result being close to the rejection limit is due to the sample size. Even though these individuals were not included in the most vulnerable group, it is known that renal structural changes occur with aging and these can have an impact on the excretion of medication, increasing toxicity of co-administered medications and chances of PDI. It is estimated that weight and renal volume reduce from 20% to 30% between 30 and 90 years of age, the number of glomeruli is reduced 30% to 50% and renal plasma flow reduces more than 600ml/min at 30 years of age and up to 300m/min at 80 years of age (16) .
There was no statistically significant association in relation to the type of HSCT. Although empirical observation has shown that allogeneic HSCT seems to have a greater tendency to develop PDIs given the use of cyclosporine. It was the only medication involved in all PDIs with anti-microbial medications, which is mandatory in this kind of transplantation and used in all the studied patients.
Fluconazole was the agent most frequently involved in PDIs, certainly due to two aspects: it was the anti-microbial medication most prescribed in the studied sample (45.7%) and is an enzymatic inhibitor of the cytochrome system P450 (CYP450) of isoenzymes CYP2C8/9, CYP2C19 and CYP3A4 responsible for metabolizing various medications used in HSCT (3) (4) 7, 10) .
Most of the PDIs could increase the serum levels of the object medication, especially cyclosporine, since this immunosuppressive drug was involved in PDIs with three antimicrobial medications. Even though the object agent is the same in each PDI, the clinical implication depends on the effect caused by precipitants (fluconazole, ciprofloxacin, and sulfamethoxazole+trimethoprim).
Cyclosporine is a substrate of the isoenzyme CYP3A4 and its co-administration with fluconazole tends to increase the pharmacological effects and toxicity of the immunosuppressant drug evidenced through nephrotoxicity, cholestasis or paresthesias (3) (4) . Hence, even though toxicity was not assessed, almost half of the patients undergoing allogeneic HSCT (n=24) were exposed to this PDI. In a previous study, this DI was also identified in patients treated with antifungal drugs (17) .
Sulfamethoxazole+trimethoprim was prescribed to
HSCT patients at the beginning of the conditioning phase as prophylaxis for Pneumocistis carinii and the therapy was interrupted on day 1. However, cyclosporine was introduced on day 1, a situation that certainly predisposes one to PDIs, and may increase nephrotoxicity and the risk of graft rejection (3) (4) 13) . The enzymatic inhibition process triggered by sulfamethoxazole+trimethoprim is slow and even if it is suspended on day 1, the effects accruing from the PDI should be carefully monitored, especially on those patients with nephrotoxicity (3) (4) 7, 13, 18) ..
In relation to the PDI ciprofloxacin+cyclosporine, a case report of a patient with bone marrow aplasia showed that the mixed therapy resulted in increased immunosuppressive serum levels, though with no severe consequences occurred due to the timeliness in adjusting the drug dosage (19) .
The onset time of interactions was delayed in most cases (61.5%), which is an additional reason to monitor patients during the entire follow-up period Even though more than half of PDIs were noted based on scientific evidence that came from non-controlled studies, these originated from information bases respected in the scientific milieu. The Drug Interaction Facts (3) was considered to be highly accurate when compared to other PDI screening sources, with a sensitivity of specificity of 97% (20) . Also the author of this compendium is one of the main information sources concerning DIs, hence it is used in various studies (8) (9) 11, 14) .
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In relation to the risk of mixed therapies, The PDI analysis included only the potentially interactive anti-microbial medications, an aspect that certainly led to an underestimated occurrence of PDIs. Finally, the PDI outcomes were not evaluated, but only the risk of patients to be exposed to a PDI.
Conclusion
PDIs involving the anti-microbial drugs fluconazole, ciprofloxacin and sulfamethoxazole+trimethoprim predominantly presented moderate severity. Even then alterations of medications' serum levels are indicated due to potential clinical implications, especially for cyclosporine, which can lead to adverse outcomes such as graft rejection (reduced serum levels) and nephrotoxicity (increased serum levels). These are delayed effects but they can have an impact on the morbidity and mortality of patients undergoing HSTC. Evidence concerning PDIs originate from non-controlled studies that do not refer to essential clinical studies or controlled studies that could corroborate or refute data obtained from case reports.
However, the combined therapy utilizing anti-microbial drugs and object-medication such as cyclosporine, essential in allogeneic HSCT, can be safe if professionals share responsibility in relation to the control of serum levels of such agents. Among other factors, responsibility may include a possible dosage adjustment and rigorous monitoring of effects that accrue from PDIs, especially for individuals in risk groups, such as being older than 30 years of age and using four or more medication.
